$ACTU
ACTUATE THERAPEUTICS, INC. Stock $actu

$actu Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000168316824006623 Filed on September 24, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.636M	$1.063M	$3.266M
YoY Change
% of Gross Profit
Research & Development	$3.757M	$4.373M	$21.71M
YoY Change	-34.79%	-8.47%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$5.393M	$5.435M	$24.97M
YoY Change	-16.72%	-2.67%
Operating Profit	-$5.393M	-$5.435M
YoY Change	-16.72%	-2.67%
Interest Expense	-$1.115M	-$896.4K	$309.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$578.1K	-$1.137M	-$79.82K
YoY Change	-519.65%	-1990.43%
Pretax Income	-$5.971M	-$6.572M	-$24.74M
YoY Change
Income Tax
% Of Pretax Income
Net Earnings	-$5.971M	-$6.572M	-$24.74M
YoY Change	-5.79%	18.97%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.55	-$4.20
Diluted Earnings Per Share	-$0.55	-$4.20	-$1.30
COMMON SHARES
Basic Shares Outstanding	19.53M shares	1.566M shares
Diluted Shares Outstanding	10.77M shares	1.566M shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$13.52M	$351.7K
YoY Change
Cash & Equivalents	$13.52M	$351.7K	$2.959M
Short-Term Investments
Other Short-Term Assets	$739.3K	$198.0K
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$14.26M	$549.7K	$2.996M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$1.181M
YoY Change
Total Long-Term Assets	$0.00	$1.181M	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$14.26M	$549.7K	$2.996M
Total Long-Term Assets	$0.00	$1.181M	$0.00
Total Assets	$14.26M	$1.731M	$2.996M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.330M	$5.893M	$3.422M
YoY Change
Accrued Expenses	$6.167M	$7.280M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$6.900M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$8.497M	$20.07M	$6.921M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt	$405.0K	$405.0K
YoY Change
Other Long-Term Liabilities	$1.690K	$1.331M
YoY Change
Total Long-Term Liabilities	$406.7K	$1.736M	$1.523M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.497M	$20.07M	$6.921M
Total Long-Term Liabilities	$406.7K	$1.736M	$1.523M
Total Liabilities	$8.904M	$21.81M	$8.444M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings	-$125.9M	-$120.0M	-$105.1M
YoY Change
Common Stock	$20.00	$2.00	$2.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.359M	-$114.3M	-$99.63M
YoY Change
Total Liabilities & Shareholders Equity	$14.26M	$1.731M	$2.996M
YoY Change

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q4
OPERATING ACTIVITIES
Net Income	-$5.971M	-$6.572M	-$24.74M
YoY Change	-5.79%	18.97%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$9.149M	-$2.674M	-$16.27M
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$1.671M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	22.32M	957.1K	1.671M
YoY Change
NET CHANGE
Cash From Operating Activities	-9.149M	-2.674M	-16.27M
Cash From Investing Activities
Cash From Financing Activities	22.32M	957.1K	1.671M
Net Change In Cash	13.17M	-1.717M	-14.60M
YoY Change
FREE CASH FLOW
Cash From Operating Activities	-$9.149M	-$2.674M	-$16.27M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-42139
	dei	Entity Registrant Name EntityRegistrantName	Actuate Therapeutics, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-3044785
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1751 River Run
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 400
	dei	Entity Address City Or Town EntityAddressCityOrTown	Fort Worth
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	76107
	dei	City Area Code CityAreaCode	817
	dei	Local Phone Number LocalPhoneNumber	887-8455
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.000001 per share
	dei	Trading Symbol TradingSymbol	ACTU
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	us-gaap	Deferred Costs DeferredCosts	1181139	usd
CY2023Q4	us-gaap	Deferred Costs DeferredCosts	0	usd
CY2024Q2	us-gaap	Assets Assets	1730826	usd
CY2023Q4	us-gaap	Assets Assets	2995566	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	5893034	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3421840	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6932367	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3221254	usd
CY2024Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	6900000	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	20072998	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6920594	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	1260903	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	988049	usd
CY2024Q2	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	70096	usd
CY2023Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	130041	usd
CY2024Q2	us-gaap	Accounts Payable Other Current And Noncurrent AccountsPayableOtherCurrentAndNoncurrent	404991	usd
CY2023Q4	us-gaap	Accounts Payable Other Current And Noncurrent AccountsPayableOtherCurrentAndNoncurrent	404991	usd
CY2024Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1735990	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1523081	usd
CY2024Q2	us-gaap	Liabilities Liabilities	21808988	usd
CY2023Q4	us-gaap	Liabilities Liabilities	8443675	usd
CY2024Q2	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.000001
CY2023Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.000001
CY2023Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	33463018	shares
CY2024Q2	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	24678355	shares
CY2024Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	24678355	shares
CY2023Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	24678355	shares
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	24678355	shares
CY2024Q2	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	124891347	usd
CY2023Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	121033336	usd
CY2024Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	94178404	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	94178404	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	38108584	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	38108584	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1690760	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1690760	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1690760	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1690760	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	2	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	5706231	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	5468006	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-119962799	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-105094521	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-114256566	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-99626513	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1730826	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2995566	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4372805	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4777242	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11233235	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9300999	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1062644	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	807177	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1975468	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1581976	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	5435449	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	5584419	usd
	us-gaap	Operating Expenses OperatingExpenses	13208703	usd
	us-gaap	Operating Expenses OperatingExpenses	10882975	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5435449	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5584419	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13208703	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10882975	usd
CY2024Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	240339	usd
CY2023Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	50194	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	272854	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	45090	usd
CY2024Q2	ACTU	Loss On Issuance Of Related Party Convertible Notes Payable At Fair Value LossOnIssuanceOfRelatedPartyConvertibleNotesPayableAtFairValue	200000	usd
CY2023Q2	ACTU	Loss On Issuance Of Related Party Convertible Notes Payable At Fair Value LossOnIssuanceOfRelatedPartyConvertibleNotesPayableAtFairValue	-0	usd
	ACTU	Loss On Issuance Of Related Party Convertible Notes Payable At Fair Value LossOnIssuanceOfRelatedPartyConvertibleNotesPayableAtFairValue	400000	usd
	ACTU	Loss On Issuance Of Related Party Convertible Notes Payable At Fair Value LossOnIssuanceOfRelatedPartyConvertibleNotesPayableAtFairValue	-0	usd
CY2024Q2	ACTU	Change In Estimated Fair Value Of Related Party Convertible Notes Payable ChangeInEstimatedFairValueOfRelatedPartyConvertibleNotesPayable	700000	usd
CY2023Q2	ACTU	Change In Estimated Fair Value Of Related Party Convertible Notes Payable ChangeInEstimatedFairValueOfRelatedPartyConvertibleNotesPayable	-0	usd
	ACTU	Change In Estimated Fair Value Of Related Party Convertible Notes Payable ChangeInEstimatedFairValueOfRelatedPartyConvertibleNotesPayable	1000000	usd
	ACTU	Change In Estimated Fair Value Of Related Party Convertible Notes Payable ChangeInEstimatedFairValueOfRelatedPartyConvertibleNotesPayable	-0	usd
CY2024Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	5076	usd
CY2023Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	5062	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	10152	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	33516	usd
CY2024Q2	us-gaap	Interest Income Operating And Nonoperating InterestIncomeOperatingAndNonoperating	8645	usd
CY2023Q2	us-gaap	Interest Income Operating And Nonoperating InterestIncomeOperatingAndNonoperating	115389	usd
	us-gaap	Interest Income Operating And Nonoperating InterestIncomeOperatingAndNonoperating	23431	usd
	us-gaap	Interest Income Operating And Nonoperating InterestIncomeOperatingAndNonoperating	167040	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1136770	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	60133	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1659575	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	88434	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-6572219	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-5524286	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14868278	usd
	us-gaap	Net Income Loss NetIncomeLoss	-10794541	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1565777	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1565777	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1422164	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1422164	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1550456	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1550456	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1381734	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1381734	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.20
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.20
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.88
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.88
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-9.59
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-9.59
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.81
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.81
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-99626513	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	148206	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-8296059	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-107774366	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	90019	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-6572219	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-114256566	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-75305432	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	73131	usd
CY2023Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	206821	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-5270255	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-80502556	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	73131	usd
CY2023Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	114679	usd
CY2023Q2	ACTU	Stock Issued During Period Value New Issues1 StockIssuedDuringPeriodValueNewIssues1	0	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	0	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-5524286	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-85953711	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14868278	usd
	us-gaap	Net Income Loss NetIncomeLoss	-10794541	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	238225	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	146262	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	272854	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	45090	usd
	ACTU	Loss On Issuance Of Related Party Convertible Note Payable At Fair Value LossOnIssuanceOfRelatedPartyConvertibleNotePayableAtFairValue	400000	usd
	ACTU	Loss On Issuance Of Related Party Convertible Note Payable At Fair Value LossOnIssuanceOfRelatedPartyConvertibleNotePayableAtFairValue	0	usd
	ACTU	Change In Estimated Fair Value Of Related Party Convertible Note Payable ChangeInEstimatedFairValueOfRelatedPartyConvertibleNotePayable	1000000	usd
	ACTU	Change In Estimated Fair Value Of Related Party Convertible Note Payable ChangeInEstimatedFairValueOfRelatedPartyConvertibleNotePayable	0	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	10152	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	33516	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	161071	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-5245	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2412458	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	206823	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	0	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-132033	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	2774440	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	14566	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7921220	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10475072	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	5500000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	185730	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	-0	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	4134516	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5314270	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4134516	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2606950	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-6340556	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2958659	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20449310	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	351709	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14108754	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	ACTU	Deferred Offering Costs Unpaid And Accrued DeferredOfferingCostsUnpaidAndAccrued	995409	usd
	ACTU	Deferred Offering Costs Unpaid And Accrued DeferredOfferingCostsUnpaidAndAccrued	0	usd
	ACTU	Estimated Fair Market Value Of Warrants Issued To Placement Agent In Connection With Issuance Of Redeemable Convertible Preferred Stock EstimatedFairMarketValueOfWarrantsIssuedToPlacementAgentInConnectionWithIssuanceOfRedeemableConvertiblePreferredStock	0	usd
	ACTU	Estimated Fair Market Value Of Warrants Issued To Placement Agent In Connection With Issuance Of Redeemable Convertible Preferred Stock EstimatedFairMarketValueOfWarrantsIssuedToPlacementAgentInConnectionWithIssuanceOfRedeemableConvertiblePreferredStock	93863	usd
CY2024Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-1.8 reverse stock split
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	351709	usd
CY2024Q2	ACTU	Working Capital WorkingCapital	-19523311	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_zcXDlvdffTv7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_86A_zrD5yYsAE3y3">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions, and judgements that affect the reported amounts of assets, liabilities, expenses, and related disclosures in the accompanying notes. The Company bases its estimates, assumptions and judgements on historical experience when available and on various factors that it believes to be reasonable under the circumstances as of the date of the accompanying unaudited condensed consolidated financial statements including the fair value of common stock, fair value of the warrant liability, fair value of Related Party Convertible Notes Payable, stock-based compensation expense, accrued expenses (including accrued expenses related to research and development (“R&D”) as described below), and the recoverability of the Company’s net deferred tax assets and related valuation allowance. In addition, other factors may affect estimates, including the expected business and operational changes, the sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Actual results could differ materially from the estimates and assumptions used in the preparation of the accompanying unaudited condensed consolidated financial statements under different assumptions or conditions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
CY2024Q2	us-gaap	Deferred Offering Costs DeferredOfferingCosts	1181139	usd
CY2023Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0	usd
CY2024Q2	ACTU	Related Party Convertibles Notes Payable RelatedPartyConvertiblesNotesPayable	200000	usd
	ACTU	Related Party Convertibles Notes Payable RelatedPartyConvertiblesNotesPayable	400000	usd
CY2023Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	988049	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	272854	usd
CY2024Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1260903	usd
CY2024Q1	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	5500000	usd
	ACTU	Loss On Issuance Of Related Party Convertible Notes Payable At Fair Value LossOnIssuanceOfRelatedPartyConvertibleNotesPayableAtFairValue	400000	usd
CY2024Q2	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	5900000	usd
	ACTU	Change In Estimated Fair Value Of Related Party Convertible Notes Payable ChangeInEstimatedFairValueOfRelatedPartyConvertibleNotesPayable	1000000	usd
CY2024Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	6900000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	6932367	usd
CY2023Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	3221254	usd
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	38108584	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000001
CY2023Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	33463018	shares
CY2023Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.000001
CY2024Q2	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	33463018	shares
CY2024Q2	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	24678355	shares
CY2024Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	24678355	shares
CY2024Q2	us-gaap	Temporary Equity Aggregate Amount Of Redemption Requirement TemporaryEquityAggregateAmountOfRedemptionRequirement	96715222	usd
CY2024Q2	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	124891347	usd
CY2024Q2	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	13710379	shares
CY2023Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	33463018	shares
CY2023Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	24678355	shares
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	24678355	shares
CY2023Q4	us-gaap	Temporary Equity Aggregate Amount Of Redemption Requirement TemporaryEquityAggregateAmountOfRedemptionRequirement	96715222	usd
CY2023Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	121033336	usd
CY2023Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	13710379	shares
CY2024Q2	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	0	usd
CY2023Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	0	usd
CY2024Q2	us-gaap	Preferred Stock Convertible Conversion Ratio PreferredStockConvertibleConversionRatio	0.555555	pure
	us-gaap	Preferred Stock Voting Rights PreferredStockVotingRights	The holders of Redeemable Convertible Preferred Stock shall have the right to one vote for each whole share of common stock into which such Redeemable Convertible Preferred Stock could then be converted.
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	38108584	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1690760	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1690760	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1690760	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1690760	shares
CY2024Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	15486699	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	265566	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.14
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	127780	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.68
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	393346	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.97
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	90019	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	73131	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	238225	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	146262	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-6572219	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-5524286	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14868278	usd
	us-gaap	Net Income Loss NetIncomeLoss	-10794541	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1565777	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1565777	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1422164	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1422164	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1550456	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1550456	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1381734	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1381734	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.20
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.20
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.88
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.88
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-9.59
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-9.59
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.81
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.81
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15097643	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14123237	shares
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001683168-24-006623-index-headers.html	Edgar Link	pending
0001683168-24-006623-index.html	Edgar Link	pending
0001683168-24-006623.txt	Edgar Link	pending
0001683168-24-006623-xbrl.zip	Edgar Link	pending
actu-20240630.xsd	Edgar Link	pending
actuate_ex1001.htm	Edgar Link	pending
actuate_ex3101.htm	Edgar Link	pending
actuate_ex3102.htm	Edgar Link	pending
actuate_ex3201.htm	Edgar Link	pending
actuate_i10q-063024.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
actu-20240630_def.xml	Edgar Link	unprocessable
actu-20240630_cal.xml	Edgar Link	unprocessable
actu-20240630_lab.xml	Edgar Link	unprocessable
actu-20240630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
actuate_i10q-063024_htm.xml	Edgar Link	completed
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ACTU
ACTUATE THERAPEUTICS, INC. Stock $actu

2024 Q3 Form 10-Q Financial Statement

#000168316824006623 Filed on September 24, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ACTU ACTUATE THERAPEUTICS, INC. Stock $actu

2024 Q3 Form 10-Q Financial Statement

#000168316824006623 Filed on September 24, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ACTU
ACTUATE THERAPEUTICS, INC. Stock $actu